Breaking

The Fed Is The New Waffle House
Anti-immigrant anger rises at scene of German market attack
‘Her Story’: China’s answer to ‘Barbie’ becomes latest smash hit. But some men are not amused
After years of war, 6.8 million Ukrainian refugees’ lives are still mired in uncertainty
Palestinian Authority unable to dislodge militants in sprawling West Bank camp
Ex-US fighter pilot accused of training Chinese military to be extradited to the United States
Lac Carheil Expanded Footprint, Drilling Fully Permitted
Charbone Hydrogene annonce des changements au sein du conseil d’administration

Investing
Stock
Economy
Latest News
Search for:

Investing

Completion of preclinical data package for RAD 402

By admin December 10, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced Completion of preclinical data package for RAD 402

Download the PDF here.

This post appeared first on investingnews.com

0

admin

Website

Related Posts

CHARBONE Hydrogen Announces Changes to Board of Directors

December 23, 2024

Charbone Hydrogene annonce des changements au sein du conseil d’administration

December 23, 2024

Lac Carheil Expanded Footprint, Drilling Fully Permitted

December 23, 2024

Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!

Your name
Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Cryptocurrency Prices

Please enter CoinGecko Free Api Key to get this plugin works.

Disclaimer: dividendsmarket.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 dividendsmarket.com
Latest News
About DividendsMarket

Type above and press Enter to search. Press Esc to cancel.